![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Samaritan Pharma has moved from the pink sheets to the AMEX, a move many investors have been waiting on for some time. Samaritan's formulation of Anticort completed Phase I and has moved on to the next phase with hopes for "fast track" approvals by many investors. There are other offerings in the pipeline. This forum is for exchange of ideas on: new developments for the company; whether it can grow to the next level; and whether the old controversies about STGI and SPHC from the pink sheet days will re-emerge. Everybody play nice ... | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |